Testing a new drug for ovarian cancer that resists platinum chemo
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial studies a new drug, misetionamide, given alone or with gemcitabine, for people with ovarian, fallopian tube, or primary peritoneal cancer that no longer responds to platinum-based chemotherapy. The goal is to see if the drug is safe and if it can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have ovarian, fallopian tube, or primary peritoneal cancer that is resistant to platinum chemotherapy (your cancer grew within 6 months of your last platinum treatment).
- You have had no more than 2 previous treatments for platinum-resistant disease.
- You are able to get a CT or MRI scan that shows at least one measurable tumor that has not been biopsied or irradiated (unless it has grown since treatment).
- You are age 18 or older and have a good performance status (ECOG 0 or 1, meaning you are fully active or able to do light work).
- Your recent blood tests show adequate kidney, liver, and bone marrow function (specific limits will be checked by your doctor).
- You have not had other cancer treatments (chemo, radiation, or experimental drugs) within the past 3-4 weeks, and any side effects from prior treatments have resolved to mild or baseline levels.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new oral drug called NMS-03305293 for women with recurrent ovarian cancer. It may work by targeting a specific protein involved in cancer growth. You may be eligible if you have high-grade serous ovarian cancer, have had limited prior treatments, and do not have a BRCA mutation.
This study tests a new drug (INCB123667) given as a pill, compared to standard chemotherapy, for people whose ovarian cancer has stopped responding to platinum-based treatments and whose tumor has high levels of a protein called Cyclin E1. The goal is to see if the new drug works better than standard chemo for this specific type of cancer.
This trial tests a new drug called IMNN-001 combined with standard chemotherapy for women with advanced ovarian, fallopian tube, or peritoneal cancer. The goal is to see if adding this drug can improve safety and effectiveness.
This trial tests a new drug called JSKN003 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if this drug can shrink tumors or slow cancer growth. If you qualify, you may receive this experimental treatment and be closely monitored by a study team.
This study tests a new drug called SHR-A1921 for people with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
This study tests a drug called mirvetuximab soravtansine (MIRV) for people with ovarian cancer that has a specific protein (FRα). It aims to see how well the drug works in real-world settings, either alone or with other treatments.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.